



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

BioDiem Ltd Prof Arthur Li directorship

Melbourne, 24 December 2014:

Prof Arthur Li has been a member of the BioDiem Ltd board since May 2010. Prof Li is also a member of international company boards some of which restrict the number of other directorships which can be held. Therefore Prof Li has stepped down from the BioDiem board as a director, however he will retain a strong interest in the company. Prof Li's brother, Sir David K.P. Li remains a major shareholder of BioDiem Ltd.

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other *vaccine* and *infectious disease treatment* companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com
Twitter @biodiem